Authors

Vinata Vedam-Mai, University of Florida
Karl Deisseroth, Stanford University
James Giordano, Georgetown University Medical Center
Gabriel Lazaro-Munoz, Baylor College of Medicine
Winston Chiong, University of California
Nanthia Suthana, University of California, Los Angeles
Jean-Philippe Langevin, University of California, Los Angeles
Jay Gill, University of California, Los Angeles
Wayne Goodman, Baylor College of Medicine
Nicole R Provenza, Brown University
Casey H Halpern, Stanford University Medical Center
Rajat S Shivacharan, Stanford University Medical Center
Tricia N Cunningham, Stanford University Medical Center
Sameer A Sheth, Baylor College of Medicine
Nader Pouratian, University of California, Los Angeles
Katherine W Scangos, University of California, San Francisco
Helen S Mayberg, Icahn School of Medicine at Mount Sinai
Andreas Horn, University Medicine Berlin
Kara A Johnson, University of Utah
Christopher R Butson, University of Utah
Ro'ee Gilron, University of California, San Francisco
Coralie de Hemptinne, University of Florida
Robert Wilt, University of California, San Francisco
Maria Yaroshinsky, University of California, San Francisco
Simon Little, University of California, San Francisco
Philip Starr, University of California, San Francisco
Greg Worrell, Mayo Clinic
Prasad Shirvalkar, University of California, San Francisco
Edward Chang, University of California, San Francisco
Jens Volkmann, Universitätsklinikum Würzburg
Muthuraman Muthuraman, University Medical Center of the Johannes Gutenberg-University Mainz
Sergiu Groppa, University Medical Center of the Johannes Gutenberg-University Mainz
Andrea A Kühn, Universitätsmedizin Berlin
Luming Li, Tsinghua University
Matthew Johnson, University of Minnesota
Kevin J Otto, University of Florida
Robert Raike, Restorative Therapies Group Implantables
Steve Goetz, Restorative Therapies Group Implantables
Chengyuan Wu, Thomas Jefferson University HospitalFollow
Peter Silburn, The University of Queensland
Binith Cheeran, Abbott
Yagna J Pathak, Abbott
Mahsa Malekmohammadi, Boston Scientific Neuromodulation
Aysegul Gunduz, University of Florida
Joshua K Wong, University of Florida
Stephanie Cernera, University of Florida
Aparna Wagle Shukla, University of Florida
Adolfo Ramirez-Zamora, University of Florida
Wissam Deeb, University of Massachusetts
Addie Patterson, University of Florida
Kelly D Foote, University of Florida
Michael S Okun, University of Florida

Document Type

Article

Publication Date

4-19-2021

Comments

This article is the author’s final published version in Frontiers in Human Neuroscience, Volume 15, April 2021, Article number 644593

The published version is available at https://doi.org/10.3389/fnhum.2021.644593. Copyright © Vedam-Mai et al.

Abstract

We estimate that 208,000 deep brain stimulation (DBS) devices have been implanted to address neurological and neuropsychiatric disorders worldwide. DBS Think Tank presenters pooled data and determined that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. The DBS Think Tank was founded in 2012 providing a space where clinicians, engineers, researchers from industry and academia discuss current and emerging DBS technologies and logistical and ethical issues facing the field. The emphasis is on cutting edge research and collaboration aimed to advance the DBS field. The Eighth Annual DBS Think Tank was held virtually on September 1 and 2, 2020 (Zoom Video Communications) due to restrictions related to the COVID-19 pandemic. The meeting focused on advances in: (1) optogenetics as a tool for comprehending neurobiology of diseases and on optogenetically-inspired DBS, (2) cutting edge of emerging DBS technologies, (3) ethical issues affecting DBS research and access to care, (4) neuromodulatory approaches for depression, (5) advancing novel hardware, software and imaging methodologies, (6) use of neurophysiological signals in adaptive neurostimulation, and (7) use of more advanced technologies to improve DBS clinical outcomes. There were 178 attendees who participated in a DBS Think Tank survey, which revealed the expansion of DBS into several indications such as obesity, post-traumatic stress disorder, addiction and Alzheimer’s disease. This proceedings summarizes the advances discussed at the Eighth Annual DBS Think Tank.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

33953663

Language

English

Share

COinS